Societal CDMO, Inc. is a bi-coastal contract development and manufacturing organization (CDMO). The Company is engaged in spanning pre-investigational new drug development to commercial manufacturing and packaging for a range of therapeutic dosage forms with a primary focus in the area of small molecules. It is a CDMO providing therapeutic development, end-to-end regulatory support, clinical and commercial manufacturing, aseptic fill/finish, lyophilization, packaging and logistics services to the global pharmaceutical market. The Company's key products include Ritalin LA, Focalin XR, Verelan PM, Verelan SR, Verapamil PM, Verapamil SR and Donnatal liquids and tablets. Its manufacturing and development capabilities include product development from formulation through clinical trial and commercial manufacturing, and specialized capabilities for solid oral dosage forms, with specialization in modified release technologies and facilities to handle potent compounds and controlled substances.

Employees

258

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Delayed Nyse Other stock markets 04:00:00 2024-04-05 pm EDT			5-day change	1st Jan Change
1.100 ^USD	+0.92%		-.--%	-

24-08-07	QHP Capital Announces the Appointment of Owen Murray as the New CEO of the Combined Bend Bioscience, CoreRx, and Societal Entities	CI
24-04-08	Societal CDMO, Inc. Announces Board and Committee Resignations	CI

Capitalization	116M 101M 91.69M 87.47M 159M 10.73B 165M 1.09B 433M 5.14B 436M 427M 18.52B	P/E ratio 2022	-4.34x	P/E ratio 2023	-2.5x
Enterprise value	151M 131M 119M 113M 206M 13.9B 214M 1.41B 561M 6.65B 565M 553M 23.98B	EV / Sales 2022	1.72x	EV / Sales 2023	0.75x
Free-Float	65.05%	Yield 2022 *	-	Yield 2023	-

24-08-07	QHP Capital Announces the Appointment of Owen Murray as the New CEO of the Combined Bend Bioscience, CoreRx, and Societal Entities	CI
24-04-08	Societal CDMO, Inc. Announces Board and Committee Resignations	CI
24-04-07	Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from NASDAQ Composite Index	CI
24-04-07	CoreRx, Inc. completed the acquisition of Societal CDMO, Inc. from First Light Asset Management, LLC and Others.	CI
24-04-07	Societal CDMO, Inc.(NasdaqCM:SCTL) dropped from S&P TMI Index	CI
24-03-22	Societal CDMO, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
24-03-21	Societal CDMO, Inc. Auditor Raises 'Going Concern' Doubt	CI
24-02-29	Stephens Downgrades Societal CDMO to Equalweight From Overweight, Raises Price Target to $1.10 From $1	MT
24-02-29	William Blair Downgrades Societal CDMO to Market Perform From Outperform	MT
24-02-29	Wall Street Set to Open Higher Thursday as Inflation Data Meets Forecasts	MT
24-02-29	Investors Await Slate of Economic Data as US Futures Move Lower in Thursday's Premarket Session	MT
24-02-29	RBC Downgrades Societal CDMO to Sector Perform From Outperform, Trims Price Target to $1.10 From $1.25 Amid CoreRx Deal	MT
24-02-27	CoreRx, Inc. entered into a definitive agreement to acquire Societal CDMO, Inc..	CI

24-02-29	Stephens Downgrades Societal CDMO to Equalweight From Overweight, Raises Price Target to $1.10 From $1	MT
24-02-29	William Blair Downgrades Societal CDMO to Market Perform From Outperform	MT
24-02-29	RBC Downgrades Societal CDMO to Sector Perform From Outperform, Trims Price Target to $1.10 From $1.25 Amid CoreRx Deal	MT
23-11-09	RBC Cuts Price Target on Societal CDMO to $1.25 From $2, Keeps Outperform Rating	MT
23-08-28	Craig Hallum Cuts Societal CDMO Price Target to $4 From $6, Maintains Buy Rating	MT

Societal CDMO, Inc. Stock

Equities

SCTL

US75629F1093

Pharmaceuticals

Valuation: Societal CDMO, Inc.

Latest news: Societal CDMO, Inc.

Analysts' recommendations: Societal CDMO, Inc.

Press Releases: Societal CDMO, Inc.

News in other languages: Societal CDMO, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Societal CDMO, Inc.

ETFs: Societal CDMO, Inc.

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

24-04-08	Societal CDMO : Acquisition/Asset Disposal - Form 8-K	PU
24-04-08	CoreRx, Inc. Completes Acquisition of Societal CDMO, Inc.	BU
24-03-22	Societal CDMO: Q4 Earnings Snapshot	AQ
24-03-13	SOCIETAL CDMO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Societal CDMO, Inc. - SCTL	BU
24-03-01	SOCIETAL CDMO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Societal CDMO, Inc. - SCTL	BU

Manager	Title	Age	Since
Owen Murray CEO	Chief Executive Officer	-	2024-08-05
Jeffrey Edwards PSD	President	-	2024-04-07
Vern Davenport SEC	Corporate Secretary	-	2024-04-07

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
SOCIETAL CDMO, INC.	+0.92%	-.--%	-.--%	-1.79%	116M
ELI LILLY AND COMPANY	+0.41%	-1.91%	+21.59%	+200.16%	884B
JOHNSON & JOHNSON	+0.69%	+0.25%	+49.37%	+57.88%	586B
ABBVIE INC.	+0.81%	-2.64%	+4.57%	+42.59%	392B
ROCHE HOLDING AG	+0.50%	-3.04%	+5.40%	+23.34%	326B
ASTRAZENECA PLC	+0.49%	-1.60%	+21.14%	+33.35%	296B
NOVARTIS AG	+0.08%	-0.52%	+23.08%	+59.18%	294B
MERCK & CO., INC.	-0.16%	-1.43%	+22.06%	+7.54%	285B
AMGEN INC.	+0.01%	-2.84%	+16.75%	+56.14%	197B
GILEAD SCIENCES, INC.	+0.15%	-0.97%	+30.30%	+81.85%	180B
Average	+0.33%	-1.62%	+19.43%	+56.03%	344.05B
Weighted average by Cap.	+0.27%	-1.68%	+23.15%	+84.38%

	2022	2023
Net sales	90.21M 78.58M 71.15M 67.88M 123M 8.33B 128M 845M 336M 3.98B 339M 331M 14.37B	94.64M 82.43M 74.63M 71.2M 130M 8.74B 134M 887M 352M 4.18B 355M 348M 15.08B
Net income	-19.88M -17.32M -15.68M -14.96M -27.21M -1.84B -28.21M -186M -74.04M -878M -74.61M -73.03M -3.17B	-13.27M -11.56M -10.47M -9.99M -18.17M -1.23B -18.84M -124M -49.43M -586M -49.81M -48.76M -2.11B
Net Debt	29.21M 25.44M 23.04M 21.98M 39.98M 2.7B 41.45M 274M 109M 1.29B 110M 107M 4.65B	34.26M 29.84M 27.02M 25.78M 46.89M 3.16B 48.61M 321M 128M 1.51B 129M 126M 5.46B

3 years	0.26	1.28
5 years	0.26	3.9
10 years	0.26	19.21